中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究

中国真菌学杂志　 2021, Vol. 16 　Issue (3): 176-181.

中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究

张馨予¹, 潘开素², 罗宏², 郑冬燕¹, 郑艳青², 曹存巍¹, 梁纲³

1. 广西医科大学第一附属医院皮肤性病科, 南宁 530021;
2. 广西艾滋病防治研究重点实验室, 南宁 530021;
3. 广西医科大学基础医学院, 南宁 530022

收稿日期:2020-11-03 出版日期:2021-06-28 发布日期:2021-06-28
通讯作者: 梁纲,E-mail:liangg9507-cn@sina.com E-mail:liangg9507-cn@sina.com
作者简介:张馨予,女(回族),博士研究生在读,医师.E-mail:zhangxinyugx@163.com

In vitro susceptibility of berberine combined with antifungal agents against Talaromyces marneffei

ZHANG Xinyu¹, PAN Kaisu², LUO Hong², ZHENG Dongyan¹, ZHENG Yanqin², CAO Cunwei¹, LIANG Gang³

1. Department of Dermatology and Venereology, The First Affiliated hospital of Guangxi Medical University, Nanning 530021, China;
2. Guangxi Key Laboratory of AIDS Prevention and Treatment, Nanning 530021, China;
3. Guangxi Medical University, School of Basic Medicine Sciences, Nanning 530021, China

Received:2020-11-03 Online:2021-06-28 Published:2021-06-28

摘要/Abstract

摘要： 目的探讨小檗碱单独及与常规抗真菌药物联合使用后对马尔尼菲篮状菌酵母相的作用效果。方法采用CLSI棋盘法对21株马尔尼菲篮状菌（Talaromyces marneffei，TM）进行体外药敏试验，使用分数抑制浓度指数（FICI）判断药物相互作用：FICI≤0.5为协同作用，FICI>4为拮抗作用，0.5结果小檗碱联合常用抗真菌药物具有协同作用，协同作用率分别为：小檗碱/氟康唑（47.62%），小檗碱/伊曲康唑（66.67%），小檗碱/伏立康唑（71.43%），小檗碱/两性霉素B（71.43%），小檗碱/卡泊芬净（52.38%）。时间-杀菌实验结果显示，5组联合用药组在24 h时每毫升TM的CFU的对数值均与任意单用药物组相比下降大于等于2个单位。所有组合均未观察到拮抗作用。结论中药小檗碱体外对马尔尼菲篮状菌具有抑制作用，与常规抗真菌药联合使用可大大降低抗真菌药物对马尔尼菲篮状菌酵母相的MIC值。这结论为小檗碱联合抗真菌药应用于马尔尼菲篮状菌病的治疗提供实验室基础。

关键词: 马尔尼菲篮状菌, 小檗碱, 药敏试验, 联合治疗

Abstract: Objective To investigate the effect of berberine alone or in combination with conventional antifungal drugs on Talaromyces marneffei yeast. Methods Twenty-one isolates of T. marneffei were assayed. Drug interactions were assessed with the chequerboard technique using the CLSI microdilution method (M27-A3) with minor modifications. The fractional inhibitory concentration index (FICI) was used to classify drug interactions. Time-kill curves were used to confirm the synergistic interaction. Results Berberine/voriconazole and berberine/amphotericin B combination showed the highest percentage of synergic interaction (71.4%); followed by berberine/itraconazole (66.67%), berberine/fluconazole (47.62%), berberine/caspofungin (52.38%), respectively. Time-kill curves confirmed the synergistic interaction, no antagonistic or indifferent action was observed. Conclusions In vitro berberine could enhances the efficacy of antifungal agents against the yeast form of T. marneffei. The MIC value can be greatly reduced when combined with conventional antifungal drugs. The results indicated berberine might have a potential role in combination with antifungal agents in freating patients infected with T. marneffei.

Key words: Talaromyces marneffei, berberine, antifungal susceptibility, combined therapy

中图分类号:

张馨予, 潘开素, 罗宏, 郑冬燕, 郑艳青, 曹存巍, 梁纲. 中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究[J]. 中国真菌学杂志, 2021, 16(3): 176-181.

ZHANG Xinyu, PAN Kaisu, LUO Hong, ZHENG Dongyan, ZHENG Yanqin, CAO Cunwei, LIANG Gang. In vitro susceptibility of berberine combined with antifungal agents against Talaromyces marneffei[J]. Chinese Journal of Mycology, 2021, 16(3): 176-181.

参考文献

[1] Supparatpinyo K, Khamwan C, Baoaoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia[J]. Lancet, 1994, 344(8915): 110-113.
[2] Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China[J]. Mycopathologia, 2013, 175(1-2): 57-67.
[3] Mo D, Lix, Weil, et al. In vitro interactions of calcineurin inhibitors with conventional antifungal agents against the yeast form of Penicillium marneffei[J]. Mycopathologia, 2014, 178(3-4): 217-20.
[4] Cao C, Liu W, Li R, et al. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei[J]. J Antimicrob Chemother, 2009, 63(2): 340-342.
[5] 罗秋红,潘开素,罗宏,等.蛇床子素体外对酵母相马尔尼菲篮状菌的抗菌活性检测[J]. 中华皮肤科杂志,2019,52(4):262-265.
[6] Chang Y. Effectiveness of berberine in bacillary dysentery[J]. 中华内科杂志, 1959,(7): 741-743.
[7] Chen C, Yu Z, Li Y, et al. Effects of berberine in the gastrointestinal tract-a review of actions and therapeutic implications[J]. Am J Chin Med, 2014, 42(5): 1053-1070.
[8] Bang S, Kwon H, Hwang HS, et al. 9-O-butyl-13-(4-isopropylbenzyl) berberine, KR-72, is a potent antifungal agent that inhibits the growth of Cryptococcus neoformans by regulating gene expression [J]. PloS one, 2014, 9(10): e109863.
[9] Quan H, Cao YY, Xu Z, et al. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole[J]. Antimicrob Agents Chemother, 2006, 50(3): 1096-1099.
[10] Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans[J]. Antimicrob Agents Chemother, 1997, 41(6): 1392-1395.
[11] Quan H, Cao YY, Xu Z, et al. Potent in vitro synergism of fluconazole andberberine chloride against clinical isolates of Candida albicans resistantto fluconazole[J]. AAC, 2006, 50(3):1096-1099.
[12] Shi G, Shao J, Wang T, et al. Mechanism of berberine-mediated fluconazole-susceptibility enhancement in clinical fluconazole-resistant Candida tropicalis isolates[J]. Biomed Pharmacother, 2017, 93:709-712.
[13] Han Y, Lee JH. Berberine synergy with amphotericin B against disseminated candidiasis in mice [J]. Biol Pharm Bull, 2005, 28(3): 541-544.
[14] Sun J, Bao H, Peng Y, et al. Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies[J]. Int J Pharm, 2018, 544(1): 46-54.
[15] Kawilar R, Chaiwarith R, Supparatpinyok K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study[J]. BMC Infect Dis, 2013, 13: 464.
[16] Wong SS, Wong KH, Hui WT, et al. Differences in clinical and laboratory diagnostic characteristics of penicilliosismarneffei in human immunodeficiency virus (HIV)- and non-HIV-infected patients[J]. J Clin Microbiol, 2001, 39(12): 4535-4540.